Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12894385 | 0.88 | MAPT (0.46) | HTR2AMAPTTDP1L3MBTL1MAOB | |
| SCHEMBL12894344 | 0.82 | HTR6 (0.47) | SLC6A4KCNH2SLC6A2SLC6A3POLB | |
| SCHEMBL12894341 | 0.80 | POLB (0.45) | HTR2ASLC6A4POLBMAPTTDP1 | |
| SCHEMBL13793731 | 0.80 | MRGPRX4 (0.48) | HTR2ASLC6A4KCNH2SLC6A2SLC6A3 | |
| SCHEMBL12894330 | 0.79 | MAOB (0.49) | SLC6A4KCNH2SLC6A2SLC6A3MAOB | |
| SCHEMBL12894345 | 0.78 | PARP10 (0.48) | POLBMAPTL3MBTL1MAOBMAOA | |
| SCHEMBL12894377 | 0.77 | HPGD (0.46) | POLBMAPTMAOBMAOANPC1 | |
| SCHEMBL12894376 | 0.77 | MAPT (0.46) | POLBMAPTL3MBTL1MRGPRX4KDM4E | |
| SCHEMBL12894359 | 0.76 | FABP4 (0.41) | MAPTL3MBTL1MAOBMAOANR4A2 | |
| SCHEMBL12894340 | 0.76 | MAOB (0.44) | TDP1L3MBTL1MAOBMAOAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-7879889-B2 | administering (2S)-2-{[(2S)-2-hydroxy-3,3-dimethylbutanoyl]amino}-N-{5-[2-(phenoxymethyl)phenyl]-1,3-thiazol-2-yl}pentanamide, for the treatment of Alzheimer's disease | SANOFI-AVENTIS (FR) | 2011-02-01 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | SANOFI-AVENTIS (FR) | 2009-10-08 | — | — | US | disclosed |
| US-7563903-B2 | Acylaminothiazole derivatives, their preparation and their therapeutic use | SANOFI-AVENTIS (FR) | 2009-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253753-A1 | Therapeutic Use of Acylaminothiazole Derivatives | ACAT1, GLS2, GLS | HTR2A 1527/4885SLC6A4 1222/4885KCNH2 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.